Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model | Zendy

Hajira Bilal | Zendy; Phillip J. Bergen | Zendy; Tae Hwan Kim | Zendy; Seung Eun Chung | Zendy; Anton Y. Peleg | Zendy; Antonio Oliver | Zendy; Roger L. Nation | Zendy; Cornelia B. Landersdorfer | Zendy

Open Access

Synergistic Meropenem-Tobramycin Combination Dosage Regimens against Clinical Hypermutable Pseudomonas aeruginosa at Simulated Epithelial Lining Fluid Concentrations in a Dynamic Biofilm Model

Author(s) -

Hajira Bilal,

Phillip J. Bergen,

Tae Hwan Kim,

Seung Eun Chung,

Anton Y. Peleg,

Antonio Oliver,

Roger L. Nation,

Cornelia B. Landersdorfer

Publication year - 2019

Publication title -

antimicrobial agents and chemotherapy

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 2.07

H-Index - 259

eISSN - 1070-6283

pISSN - 0066-4804

DOI - 10.1128/aac.01293-19

Subject(s) - tobramycin , meropenem , pseudomonas aeruginosa , microbiology and biotechnology , biofilm , cystic fibrosis , medicine , chemistry , antibiotics , bacteria , biology , antibiotic resistance , genetics

Exacerbations of chronicPseudomonas aeruginosa infections are a major treatment challenge in cystic fibrosis due to biofilm formation and hypermutation. We aimed to evaluate different dosage regimens of meropenem and tobramycin as monotherapies and in combination against hypermutable carbapenem-resistantP. aeruginosa . A hypermutableP. aeruginosa isolate (meropenem and tobramycin MICs, 8 mg/liter) was investigated in the dynamic CDC biofilm reactor over 120 h.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research